is oral rehydration with a hypoosmolar solution. 1 Considering the burden of acute gastroenteritis both to children and the healthcare system, effective and inexpensive interventions that could add to the effect of oral rehydration therapy are of interest.
Recently, in many countries, gelatine tannate is being marketed for the treatment of acute gastroenteritis. Gelatine tannate consists of tannic acid suspended in a gelatine solution. It has a stable structure both in the acidic environment of the stomach as well as in basic and neutral environments such as in the small intestine and colon. 2 The specific mechanisms by which gelatine tannate may act against gastrointestinal infections remain unknown. It is known, however, that it forms a biofilm, which mechanically protects the gastrointestinal mucosa and causes precipitation of proinflammatory proteins such as mucoproteins in the intestinal mucosa. 3 In addition, it inhibits the growth of bacteria such as Bacteroides fragilis, Clostridium perfringens, Escherichia coli, Enterobacter cloacae, Salmonella typhimurium, Helicobacter pylori, Listeria monocytogenes, and in vitro mycobacterial Vibrio cholerae. 3, 4, 5 The antiinflammatory action of gelatine tannate also involves blocking inflammatory agents in the gastrointestinal mucosa. 6 F o r p e e r r e v i e w o n l y 6 At the time of designing this study, only limited evidence was available on the effectiveness of gelatine tannate in the management of acute gastroenteritis in children. This evidence is summarized in a 2014 systematic review, which only included 2 studies. Neither of the included studies evaluated the effects of gelatine tannate on outcome measures such as stool output, duration of diarrhea, need for admission to the hospital, duration of hospital stay, and (in children) weight gain after rehydration. The review concluded that there is no evidence to support the use of gelatine tannate for treating acute gastroenteritis in children and only scant evidence to support the use of gelatine tannate in adults. 7 Further studies are needed.
Thus, our aim was to assess the efficacy of gelatine tannate for the management of acute gastroenteritis in children.
METHODS

Trial design
This was a randomized, double-blind, placebo-controlled trial, conducted in 2 pediatric hospitals in Warsaw, Poland (The Medical University of Warsaw and the Niekłanska Hospital). The Ethics Committee of the Medical University of Warsaw approved the study. Parents or legal guardians were fully informed about the aims of the study, and informed written consent was obtained from them. The trial was registered at ClinicalTrials.gov (NCT02280759) before enrollment of the first patient.
The full protocol of this trial was published in BMJ Open. 8 The guidelines from the CONSORT statement were followed for reporting this trial. 9 
Participants
Intervention
Participants were randomly assigned to receive gelatine tannate or a comparable placebo in addition to standard rehydration therapy. Gelatine tannate was manufactured by ICN Polfa Rzeszów/Valeant. The manufacturer did not have role in the design or conduct of the study. The placebo contained maltodextrin. The dose of the active product or placebo was age dependent (i.e., in children younger than 3 years of age, the dose was 250 mg, and, in children older than 3 years of age, the dose was 500 mg). Both the gelatine tannate and placebo were taken orally, 4 times/day, for 5 days. All study participants were followed up for the duration of the intervention (5 days), and then for an additional 48 h. Compliance was assessed by counting the number of sachets of study products left unused. 
Study procedure
For initial rehydration, all children were treated according to 2014 European recommendations (fast oral rehydration over 3-4 h by mouth with a hypotonic solution). 1 Intravenous fluid therapy was administered during the rehydration phase if there was failure to achieve adequate rehydration within the first 3-4 hours or if there were intensified signs of dehydration despite the intake of the estimated fluid requirements. During the maintenance phase, intravenous fluid therapy was started if dehydration recurred despite the intake of estimated fluid requirements, including oral rehydration solution, for ongoing losses. After all of the signs of dehydration had disappeared, oral rehydration solution was given for ongoing losses until the diarrhea stopped. Rapid reintroduction of the previous diet after successful rehydration was recommended. At all times, breastfeeding was allowed. Children were discharged from the hospital once a stable clinical condition had been achieved.
Outcome measures
The primary outcome measure was the duration of diarrhea, defined as the time until the normalization of stool consistency according to the BSF or ASF scale (on BSF scale, numbers 2, 3, 4 and 5; on ASF scale, letters B or C) or the time until the normalization of the number of stools (compared with the period before the onset of diarrhea) as well as the presence of normal stools for 48 h. The secondary outcome measures included the need for intravenous rehydration, need for hospitalization of outpatients, number of watery stools per day, vomiting, weight gain, adverse events, recurrence of diarrhea (48 h after the intervention), severity of diarrhea according to the Vesikari scale, 11 and use of concomitant medications. 
Allocation concealment and blinding
A computer-generated randomization list prepared by a person unrelated to the trial was used to allocate participants to the study groups in blocks of eight. Consecutive randomization numbers were given to participants at enrollment. The study product was weighed, packaged, and signed by consecutive numbers according to the randomization list at the hospital pharmacy at the Medical University of Warsaw by independent personnel not involved in the conduct of the study. The study products were delivered to the physicians in small envelopes labeled with the consecutive numbers and doses. The physicians were blinded to the meaning of the numbers, and the sealed envelopes were deposited in a safe place in the administrative part of the department. The active product and placebo were packaged in identical sachets.
The contents of the sachets looked and tasted the same. Researchers, caregivers, outcome assessors, and the person responsible for the statistical analysis were blinded to the intervention until the completion of the study and the analysis of the data.
Sample size calculation
The primary outcome of the study was the duration of diarrhea. Based on available data in the literature, the average duration of acute gastroenteritis in children is 5-7 days. 1 We assumed that a clinically significant difference in the effectiveness of gelatine tannate versus placebo would shorten the duration of symptoms by 24 hours (±12 h). To detect such a difference in the duration of diarrhea between the study groups with a power of 90% and α=0.01, we determined that a sample of 60 children 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Fisher's exact test was used, as appropriate, to compare percentages. The same computer software was used to calculate the risk ratio (RR) and mean or median difference (MD), as appropriate, both with a 95% confidence interval (CI). The difference between study groups was considered significant when the 95% CI for RR did not include 1.0 and the 95% CI for MD did not include 0 (equivalent to P < 0.05).
All statistical tests were 2-tailed and performed at the 5% level of significance. All analyses were conducted on an intention-to-treat basis, including all patients in the groups to which they were randomized for whom outcomes were available.
RESULTS
Overall, 230 children with acute gastroenteritis who presented for treatment between
February 2015 and June 2017 were assessed for eligibility; 72 were enrolled in the study and randomly assigned to one the 2 study groups: 36 to the gelatine tannate group and 36 to the placebo group. Eight children were lost to follow-up. Sixty-four 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y children (89%) completed the intervention and were included in the analysis ( Figure   1 ). Baseline demographic and clinical characteristics are shown in Table 1 . The two groups were comparable in regard to these characteristics at study entry. 
Primary and secondary outcomes
The primary and secondary outcome measures are presented in Table 2 . The duration of diarrhea after randomization was similar in both groups (MD 0.1 h, 95% CI -14.1 to 14.3). The risk of unscheduled intravenous rehydration was similar in the gelatine tannate and placebo groups (RR 0.99; 95% CI 0.78 to 1.25). The number of watery stools per day was similar in both groups throughout the study period (for details -see Table 2 ). In both groups, the risk of vomiting (RR 1.27, 95% CI 0.93 to 1.73), weight gain (MD -59.1 g, 95% CI -133.1 to 15), risk of recurrence of diarrhea 48 
DISCUSSION
Principal findings
This randomized, double-blind, placebo-controlled study showed that in children younger than 5 years with acute gastroenteritis, administration of gelatine tannate compared with placebo was ineffective as an adjunct to oral rehydration therapy.
Strengths and limitations
This study was a randomized controlled trial, which is the design of choice for interventional studies. The protocol of the study was published in a peer reviewed journal. We used adequate methods for the generation of the allocation sequence and allocation concealment. We maintained blinding throughout the selection, treatment, data management, and data analyses phases of the study. Follow-up was adequate; data were obtained from 89% of the participants. For assessment of the consistency of stools, we used the validated Bristol Stool Form Scale or the Amsterdam Stool Form scale, depending on the age of the participants. The sample size was predefined.
These features minimize the risk of bias. The potential limitation of this trial is that we did not assess stool volume as the primary outcome measure, which is a clinically meaningful endpoint. This decision was based on feasibility reasons and our previous negative experiences (unwillingness of parents and/or hospital nurses to collect stools).
Comparison with previous findings
Our findings are in contrast with the findings of two, recent, randomized controlled trials that assessed the effectiveness of administering gelatin tannate for treatment of acute gastroenteritis in children. The 2017 study by Mennini et al. 13 There are several possible reasons for the differences in findings. First, in contrast to the study by Mennini et al., our study had a double-blind design, which reduces the risk of performance and detection biases. The study by Mennini et al. did not provide the sample size calculation, which is needed to avoid false positive and false negative conclusions. In our study, we included children with diarrhea lasting for no longer than 5 days compared to no longer than 3 days in the study by Mennini et al. The lack of an effect in our study may suggest that in order for gelatine tannate to be effective, it has to be administered early in the course of the disease. In both studies, the duration of diarrhea was assessed. However, in contrast to our study, it was unclear how this outcome was defined in the Mennini et al. study. Mennini et al. also 40%, respectively), thus, the randomization did not work properly. In our study, the sample size was smaller. However, the sample size was based on a sample size calculation designed to detect 24 h (± 12 h) shortening of the duration of diarrhea between the study groups with a power of 90% and α=0.01; thus, a sufficient number of participants was randomized in our study, allowing us to be reasonably certain that no difference between the interventions exists. In the study by Çağan et al., 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Strengths and limitations of this study:
• This study was a randomized controlled trial, which is the design of choice for interventional studies.
• The protocol of the study was published in a peer-reviewed journal (BMJ Open).
• This study answers a specific clinical question filling a gap in knowledge about the effectiveness and safety of gelatine tannate.
• The guidelines from the CONSORT statement were followed for reporting this trial.
• A limitation of the study is the lack of assessment of stool volume, which is a clinically meaningful endpoint.
INTRODUCTION
The main objectives in the management of acute gastroenteritis are the prevention or treatment of dehydration, promotion of weight gain following rehydration, and reduction of the duration of diarrhea and quantity of stool output. The key treatment is oral rehydration with a hypoosmolar solution. 1 Considering the burden of acute gastroenteritis both to children and the healthcare system, effective and inexpensive interventions that could add to the effect of oral rehydration therapy are of interest.
Recently, in many countries, gelatine tannate is being marketed for the treatment of acute gastroenteritis. Gelatine tannate consists of tannic acid suspended in a gelatine solution. It has a stable structure both in the acidic environment of the stomach as well as in basic and neutral environments such as in the small intestine and colon. 2 At the time of designing this study, only limited evidence was available on the effectiveness of gelatine tannate in the management of acute gastroenteritis in children. This evidence is summarized in a 2014 systematic review, 7 which only included 2 studies: one randomized trial in adults and one non-randomized trial in children. Neither of the included studies evaluated the effects of gelatine tannate on outcome measures such as stool output, duration of diarrhea, need for admission to the hospital, duration of hospital stay, and (in children) weight gain after rehydration. The review concluded that there is no evidence to support the use of gelatine tannate for treating acute gastroenteritis in children (i.e., no randomized controlled trials; important outcomes not addressed) and only scant evidence to support the use of gelatine tannate in adults. Further studies are needed. Thus, our aim was to assess in the efficacy of gelatine tannate for the management of acute gastroenteritis in children. 
METHODS
Trial design
The full protocol of this trial was published in BMJ Open. 8 The guidelines from the CONSORT statement were followed for reporting this trial. 9
Participants
Eligible participants were children younger than 5 years with acute gastroenteritis, defined as a change in stool consistency to a loose or liquid form (according to the with the manufacturer's recommendation, the dose of the active product or placebo was age dependent (i.e., in children younger than 3 years of age, the dose was 250 mg, and, in children older than 3 years of age, the dose was 500 mg). Both the gelatine tannate and placebo were taken orally, 4 times/day, for 5 days. The intervention was started immediately after recruitment of the participant into the study. All study participants were followed up for the duration of the intervention (5 days), and then for an additional 48 h. Compliance was assessed by counting the number of sachets of study products left unused. As stated in the protocol of the study, based on previously published trials, we assumed that participants receiving <75% of the recommended doses were treated as noncompliant.
Study procedure
For initial rehydration, all children were treated according to 2014 European recommendations (fast oral rehydration over 3-4 h by mouth with a hypotonic solution). 1 Intravenous fluid therapy was administered during the rehydration phase if there was failure to achieve adequate rehydration within the first 3-4 hours or if there were intensified signs of dehydration despite the intake of the estimated fluid requirements. During the maintenance phase, intravenous fluid therapy was started if dehydration recurred despite the intake of estimated fluid requirements, including oral rehydration solution, for ongoing losses. After all of the signs of dehydration were discharged from the hospital once a stable clinical condition had been achieved.
Outcome measures
The primary outcome measure was the duration of diarrhea, defined as the time until 
Allocation concealment and blinding
A computer-generated randomization list prepared by a person unrelated to the trial was used to allocate participants to the study groups in blocks of eight. Consecutive randomization numbers were given to participants at enrollment. The study product was weighed, packaged, and signed by consecutive numbers according to the randomization list at the hospital pharmacy at the Medical University of Warsaw by independent personnel not involved in the conduct of the study. The study products were delivered to the physicians in small envelopes labeled with the consecutive and the sealed envelopes were deposited in a safe place in the administrative part of the department. The active product and placebo were packaged in identical sachets.
Sample size calculation
The primary outcome of the study was the duration of diarrhea. Based on available data in the literature, the average duration of acute gastroenteritis in children is 5-7 days. 1 We assumed that a clinically significant difference in the effectiveness of gelatine tannate versus placebo would shorten the duration of symptoms by 24 hours (±12 h). To detect such a difference in the duration of diarrhea between the study groups with a power of 90% and α=0.01, we determined that a sample of 60 children was needed. Assuming approximately 20% loss to follow-up, we aimed to recruit a total of 72 children for this study. The sample size calculation was performed with the Sealed Envelope Ltd. software. 12
Statistical analysis
The statistical analyses were conducted using StatsDirect version 3. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Fisher's exact test was used, as appropriate, to compare percentages. The same computer software was used to calculate the risk ratio (RR) and mean or median difference (MD), as appropriate, both with a 95% confidence interval (CI). The difference between study groups was considered significant when the 95% CI for RR did not include 1.0 and the 95% CI for MD did not include 0 (equivalent to P < 0.05).
Patient involvement
Patients were not involved in setting the study protocol and implementation, and the dissemination of the results.
RESULTS
Overall, 230 children with acute gastroenteritis who presented for treatment between
February 2015 and June 2017 were assessed for eligibility; 72 were enrolled in the study and randomly assigned to one of the 2 study groups: 36 to the gelatine tannate group and 36 to the placebo group. Eight children were lost to follow-up. Sixty-four children (89%) completed the intervention and were included in the analysis ( Figure   1 ). Baseline demographic and clinical characteristics are shown in Table 1 . The two groups were comparable in regard to these characteristics at study entry. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Primary and secondary outcomes
The primary and secondary outcome measures are presented in Table 2 . The duration of diarrhea after randomization was similar in both groups (MD 0.1 h, 95% CI -14.1 to 14.3). The risk of unscheduled intravenous rehydration was similar in the gelatine tannate and placebo groups (RR 0.99; 95% CI 0.78 to 1.25). The number of watery stools per day was similar in both groups throughout the study period (for details -see Table 2 ). In both groups, the risk of vomiting (RR 1.27, 95% CI 0.93 to 1.73), weight gain (MD -59.1 g, 95% CI -133.1 to 15), risk of recurrence of diarrhea 48 h after the intervention (RR 0.12, 95% CI 0.01 to 2.0), and severity of diarrhea according to the Vesikari scale (MD 1.1, 95% CI -0.7 to 2.9) were similar. Adverse effects were similar in both groups (RR 0.6, 95% CI 0.17 to 2.45). None of the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
DISCUSSION
Principal findings
Strengths and limitations
This study was a randomized controlled trial, which is the design of choice for interventional studies. The protocol of the study was published in a peer-reviewed journal. We used adequate methods for the generation of the allocation sequence and allocation concealment. We maintained blinding throughout the selection, treatment, data management, and data analyses phases of the study. Follow-up was adequate; data were obtained from 89% of the participants. For assessment of the consistency of stools, we used the validated Bristol Stool Form Scale or the Amsterdam Stool Form scale, depending on the age of the participants. The sample size was predefined.
These features minimize the risk of bias. A potential limitation of this trial is that we did not assess stool volume as the primary outcome measure, which is a clinically meaningful endpoint. This decision was based on feasibility reasons and our previous negative experiences (unwillingness of parents and/or hospital nurses to collect stools). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 There are several possible reasons for the differences in findings. First, in contrast to the study by Mennini et al., our study had a double-blind design, which reduces the risk of performance and detection biases. The study by Mennini et al. did not provide the sample size calculation, which is needed to avoid false positive and false negative conclusions. In our study, we included children with diarrhea lasting for no longer than 5 days compared to no longer than 3 days in the study by Mennini et al. The lack of an effect in our study may suggest that in order for gelatine tannate to be effective, it has to be administered early in the course of the disease. In both studies, the duration of diarrhea was assessed. However, in contrast to our study, it was unclear how this outcome was defined in the Mennini et al. study. Mennini et al. also assessed the number of any type of bowel movements, while we assessed the number of watery stools. Thus, these findings are not directly comparable. However, for comparison, post hoc, we evaluated the number of any type of stools. Throughout the study period, there were no differences in the number of stools per day between the study groups (data are not shown, however, are available upon request). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 40%, respectively), thus, the randomization did not work properly. In our study, the sample size was smaller. However, the sample size was based on a sample size calculation designed to detect 24 h (± 12 h) shortening of the duration of diarrhea between the study groups with a power of 90% and α=0.01; thus, a sufficient number of participants was randomized in our study, allowing us to be reasonably certain that no difference between the interventions exists. In the study by Çağan et al., while the sample size calculation was provided, it is unclear what assumptions were made by the authors. While one of the primary study endpoints in the study by Çağan et al. was the total time to resolution of diarrhea, no data relevant to this endpoint were provided; thus, a comparison between the studies is not possible.
Comparison with previous findings
Both studies reported data on watery stools. However, the data were presented 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Taken together, direct comparison of our findings with the results reported by others is difficult. It is possible that the differences in the study design and execution contributed to the differences in findings. Additionally, other factors could explain the different results seen in our study patients compared with those of previous studies, such as differences in age, socioeconomic situation, pathogen, rotavirus vaccination status, or type of oral rehydration solution used. Hypothetically, the lack of an effect observed in our study could also originate from the excessive excretion of the study product due to the duration of diarrhea. However, in our study, there were no children with severe diarrhea and/or excessive duration of diarrhea. Further well-designed and carefully conducted randomized controlled trials, with relevant inclusion/exclusion criteria, adequate sample sizes, and validated clinical outcome measures (with definitions), may help to resolve the uncertainty with regard to the efficacy of gelatine tannate in the management of acute gastroenteritis in children.
CONCLUSIONS
In summary, gelatine tannate, as dosed in this study, administered as an adjunct to rehydration for the management of acute gastroenteritis in children younger than 5 years was not effective. According to current guidelines, 1 15 the mainstay of treatment for acute gastroenteritis should be oral rehydration with a hypoosmolar solution.
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